Susan Burwig Biography and Net Worth

VP of Medpace

Susan E. Burwig serves as Executive Vice President - Operations of the Company. She joined Medpace in August 1993 and has served in various key leadership roles within the Clinical Operations department. From February 2003 to May 2015, Ms. Burwig served as Senior Vice President, Clinical Operations, overseeing clinical trial management, clinical monitoring, start-up, including feasibility, and new business proposals. In June 2015, Ms. Burwig was appointed Senior Vice President, Operations, and in January 2017 she was named as Executive Vice President, Operations. Prior to joining Medpace, Ms. Burwig held several clinical roles, including leading heart failure clinical research studies at the University of Cincinnati. Ms. Burwig received her Bachelor of Science in Nursing as well as an MA in Sports Administration from Kent State University.

What is Susan E. Burwig's net worth?: The estimated net worth of Susan E. Burwig is at least $35.22 million as of October 27th, 2026. Ms. Burwig owns 54,012 shares of Medpace stock worth more than $35,216,364 as of November 1st. This net worth approximation does not reflect any other investments that Ms. Burwig may own. Learn More about Susan E. Burwig's net worth.
How do I contact Susan E. Burwig?: The corporate mailing address for Ms. Burwig and other Medpace executives is 5375 MEDPACE WAY, CINCINNATI OH, 45227. Medpace can also be reached via phone at (513) 579-9911 and via email at [email protected]. Learn More on Susan E. Burwig's contact information.
Has Susan E. Burwig been buying or selling shares of Medpace?: Within the last three months, Susan E. Burwig has sold $13,540,000.00 of Medpace stock. Most recently, Susan E. Burwig sold 3,940 shares of the business's stock in a transaction on Tuesday, October 27th. The shares were sold at an average price of $677.00, for a transaction totalling $2,667,380.00. Following the completion of the sale, the vice president now directly owns 54,012 shares of the company's stock, valued at $36,566,124. Learn More on Susan E. Burwig's trading history.
Who are Medpace's active insiders?: Medpace's insider roster includes Kevin Brady (CFO), Susan Burwig (VP), Brian Carley (Director), Fred Davenport, Jr. (Director), Stephen Ewald (General Counsel), Jesse Geiger (CFO), Ashley Keating (Director), Tom King (Director), Robert Kraft (Director), Cornelius McCarthy, III (Director), and August Troendle (CEO). Learn More on Medpace's active insiders.
Are insiders buying or selling shares of Medpace?: In the last twelve months, insiders at the sold shares 53 times. They sold a total of 745,891 shares worth more than $449,059,813.80. The most recent insider tranaction occured on October, 27th when VP Susan E. Burwig sold 3,940 shares worth more than $2,667,380.00. Insiders at Medpace own 20.5% of the company. Learn More about insider trades at Medpace.
Information on this page was last updated on 10/27/2026.

Susan E. Burwig Insider Trading History at Medpace

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
10/27/2026	Sell	3,940	$677.00	$2,667,380.00	54,012
10/26/2026	Sell	16,060	$677.00	$10,872,620.00	57,624
7/28/2026	Sell	7,500	$600.00	$4,500,000.00	62,984
11/24/2025	Sell	20,000	$609.15	$12,183,000.00	27,500
11/11/2025	Sell	18,000	$605.00	$10,890,000.00	47,500
10/27/2025	Sell	2,000	$605.01	$1,210,020.00	65,500
9/3/2025	Sell	10,000	$480.00	$4,800,000.00	57,500
7/28/2025	Sell	7,500	$450.14	$3,376,050.00	57,500
3/15/2024	Sell	102	$403.00	$41,106.00	15,181
12/14/2023	Sell	10,391	$304.15	$3,160,422.65	17,292
6/14/2021	Sell	15,000	$178.96	$2,684,400.00	77,405
7/30/2020	Sell	6,000	$121.14	$726,840.00	46,179
8/17/2016	Buy	19,211	$29.21	$561,153.31	1,211

Susan E. Burwig Buying and Selling Activity at Medpace

Medpace Company Overview

Medpace Holdings, Inc. engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance. The company was founded by August James Troendle in 1992 and is headquartered in Cincinnati, OH.

Today's Range

Now: $652.01

$648.11

$677.85

50 Day Range

MA: $619.12

$583.16

$692.68

2 Week Range

Now: $652.01

$373.00

$693.97

Volume

219,433 shs

Average Volume

333,263 shs

Market Capitalization

$18.24 billion

P/E Ratio

36.14

Dividend Yield

N/A

Beta

1.18